We are live on ! Find out more
PMCB icon

PharmaCyte Biotech
PMCB

22 hedge funds and large institutions have $4.42M invested in PharmaCyte Biotech in 2021 Q3 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more call options, than puts

Call options by funds: $234K | Put options by funds: $140K

6.74% more ownership

Funds ownership: 0% → 6.74% (+6.7%)

Holders
22
Holders Change
+22
Holders Change %
–
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
–
Reduced
–
Closed
–
Calls
$234K
Puts
$140K
Net Calls
+$94K
Net Calls Change
+$94K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$3.55M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$470K
3
SSA
Schonfeld Strategic Advisors
New York
+$310K
4
SFI
Susquehanna Fundamental Investments
Pennsylvania
+$175K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$164K

Top Sellers

No sellers this quarter

PMCB Hedge Fund Activity: Q3 2021 in Review

22 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q3 2021, worth a combined $4.42M.

Buyers outnumbered sellers: 22 funds opened new PMCB positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $3.55M.

  • 22 institutional investors held PharmaCyte Biotech (PMCB) as of Q3 2021, up from 0 in Q2 2021.
  • Funds reported $4.42M of PharmaCyte Biotech stock for Q3 2021.
  • 22 funds opened new PharmaCyte Biotech positions in Q3 2021 and 0 closed out, a net change of +22 holders.
  • The largest PharmaCyte Biotech buyer in Q3 2021 was Sabby Management, an estimated $3.55M added.

Based on aggregated 13F filings for Q3 2021.